H. Lundbeck A/S (HLUBF)

Market Cap	5.54B
Revenue (ttm)	3.21B
Net Income (ttm)	401.88M
Shares Out	n/a
EPS (ttm)	0.41
PE Ratio	13.77
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	250
Open	4.625
Previous Close	5.250
Day's Range	4.625 - 4.625
52-Week Range	3.910 - 6.650
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 5, 2025

About H. Lundbeck

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat M...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1915
• Employees: 5,681
• Stock Exchange: OTCMKTS
• Ticker Symbol: HLUBF

Financial Performance

In 2023, H. Lundbeck's revenue was 19.91 billion, an increase of 9.13% compared to the previous year's 18.25 billion. Earnings were 2.29 billion, an increase of 19.52%.

Financial numbers in DKK